Pharmaceutical preparation containing hyaluronic acid, drug transdermal patch and preparation method thereof

A technology of transdermal patch and hyaluronic acid is applied in the field of medicine to achieve the effects of good therapeutic effect, good curative effect and simple structure

Active Publication Date: 2021-08-06
江苏一全药业有限公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing transdermal patches are still difficult to achieve long-lasting (up to 5-7 days) effective release, and new absorption enhancers may bring new risks to the human body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation containing hyaluronic acid, drug transdermal patch and preparation method thereof
  • Pharmaceutical preparation containing hyaluronic acid, drug transdermal patch and preparation method thereof
  • Pharmaceutical preparation containing hyaluronic acid, drug transdermal patch and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A1

[0082] (1) Prepare packaged medicine

[0083] Dissolve 0.28g of lorazepam in an aqueous solution containing 0.42g of hyaluronic acid (molecular weight: 11300) represented by formula (1), and then carry out the process at an air inlet temperature of about 150°C and an outlet temperature of about 80°C. Spray-dry to obtain lorazepam hyaluronic acid coating with an average particle size of 268nm.

[0084] (2) Ingredients

[0085] Encapsulated drug: prepared in this embodiment;

[0086] Unpacked drug: Lorazepam, 0.1g;

[0087] Transdermal absorption enhancer: isopropyl myristate, 0.57g;

[0088] Drug-loaded matrix: 5.6g in total, of which 3.92g is 2852 pressure-sensitive adhesive (containing carboxyl group), 1.12g is 2287 pressure-sensitive adhesive (containing hydroxyl group), 1.12g is 4098 pressure-sensitive adhesive (no functional group) 0.56g;

[0089] Solvent: propylene glycol, 0.4 g.

[0090] (3) preparation of drug transdermal patch

[0091] Mix and dissolve the unwra...

Embodiment A2

[0094] (1) Prepare packaged medicine

[0095] Dissolve 0.25g of lorazepam in an aqueous solution containing 0.45g of hyaluronic acid (molecular weight: 7800) represented by formula (1), and then carry out the process at an inlet temperature of about 150°C and an outlet temperature of about 80°C. Spray-dry to obtain lorazepam hyaluronic acid coating with an average particle size of 396nm.

[0096] (2) Ingredients

[0097] Encapsulated drug: prepared in this embodiment;

[0098] Unpacked drug: Lorazepam, 0.1g;

[0099] Transdermal absorption enhancer: isopropyl myristate, 0.42g;

[0100] Drug-loading matrix: a total of 6g, of which 4.8g is 235A pressure-sensitive adhesive (containing carboxyl group), 0.6g is 2516 pressure-sensitive adhesive (containing hydroxyl group), 0.6g is 4098 pressure-sensitive adhesive (no functional group) 0.6g;

[0101] Solvent: butylene glycol, 0.3 g.

[0102] (3) preparation of drug transdermal patch

[0103] Mix and dissolve the unwrapped drug...

Embodiment A3

[0106] (1) Prepare packaged medicine

[0107] Dissolve 0.22g of lorazepam in an aqueous solution containing 0.26g of hyaluronic acid (molecular weight: 13,200) represented by formula (1), and then carry out the process at an inlet air temperature of about 150°C and an outlet air temperature of about 80°C. Spray-dry to obtain lorazepam hyaluronic acid coating with an average particle size of 314nm.

[0108] (2) Ingredients

[0109] Encapsulated drug: prepared in this embodiment;

[0110] Unpacked drug: Lorazepam, 0.1g;

[0111] Transdermal absorption enhancer: Span 20, 0.70g;

[0112] Drug-loaded matrix: 4.67g in total, of which 2.8g is 2852 pressure-sensitive adhesive (containing carboxyl group), 1.87g is 2516 pressure-sensitive adhesive (containing hydroxyl group);

[0113] Solvent: n-butanol, 0.5 g.

[0114] (3) preparation of drug transdermal patch

[0115] Mix and dissolve the unwrapped drug prepared in this example with a solvent, and then fully mix with the wrapped...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
particle sizeaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of medicine, in particular to a pharmaceutical preparation, a drug transdermal patch containing the pharmaceutical preparation and a preparation method thereof. The pharmaceutical preparation includes encapsulated medicine and unencapsulated medicine. The encapsulated medicine includes medicine A and an inclusion material encapsulating the medicine A, and the inclusion material contains hyaluronic acid and / or its derivatives ; the unencapsulated drug is drug B; the drug A is the same as or different from the drug B; The pharmaceutical preparation and the drug transdermal patch of the present invention can release effective dose of drug persistently (up to 7 days) and stably, and have strong controllability to meet the drug needs of patients of different degrees.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical preparation, a drug transdermal patch containing the pharmaceutical preparation and a preparation method thereof. Background technique [0002] External treatment is a commonly used method in clinical practice. In the early days, it was mostly in the form of Chinese herbal plasters, which were used to apply acupoints or local injuries to achieve therapeutic effects. This treatment method is simple and easy to operate, and has a high degree of patient acceptance. [0003] In addition, for Western medicines that are traditionally taken orally or injected, transdermal patches have appeared in recent years to replace oral or injected. On the other hand, it can increase patient acceptance. However, it is still difficult for the drug to release an effective dose through the stratum corneum of the skin, and the penetration dose, stability and duration have not been ideal. In t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/70A61K47/36A61K47/69A61K47/32A61K47/26A61K47/12A61K47/10A61K47/14A61K47/22A61K31/5513A61P25/22
CPCA61K9/7023A61K31/5513A61K47/10A61K47/12A61K47/14A61K47/22A61K47/26A61K47/32A61K47/36A61K47/6949A61P25/22
Inventor 全丹毅
Owner 江苏一全药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap